Results 21 to 30 of about 85,902 (266)
Frontiers in Immunology, 2020 Advances in cancer immunity have promoted a major breakthrough in the field of cancer therapy. This is mainly associated with the successful development of immune checkpoint inhibitors (ICIs) for multiple types of human tumors.
Yuxiao Song +5 more
doaj +1 more source
Mechanisms of Resistance to Immune Checkpoint Blockade [PDF]
American Journal of Clinical Dermatology, 2018 The recent development of effective immune checkpoint inhibition (ICI), first demonstrated in melanoma, has revolutionized cancer treatment. Monoclonal antibodies blocking the immune checkpoints cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 receptor (PD-1) have shown substantial clinical benefit in a subset of patients ...
David, Liu +2 more
openaire +2 more sources
Immune checkpoint blockade in ovarian cancer [PDF]
memo - Magazine of European Medical Oncology, 2016 Increased numbers of tumour infiltrating T‑cells have long been associated with a better prognosis in ovarian cancer, which has led to the general assumption of a relevant impact of T‑cellular anti-tumour immunity in this disease. As a consequence of this knowledge, a multitude of immunologic therapies has emerged over the past years.
Weiss, Lukas +3 more
openaire +2 more sources
Corticosteroids and immune checkpoint blockade
Aging, 2015 Novel immunotherapies acting through immune checkpoint blockade to stimulate the immune response have demonstrated promising outcomes in advanced malignancies [1]. As a result, novel cancer immunotherapy was named a scientific breakthrough of the year in 2013 by Science.
Le, Min +2 more
openaire +2 more sources
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
Frontiers in Oncology, 2021 Immunotherapy has emerged as the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and targeted therapy. Immune checkpoint inhibitors are the current superheroes of immunotherapy, unleashing a patient’s own immune cells to ...
Remy Thomas +4 more
doaj +1 more source
Renal complications of immune checkpoint blockade [PDF]
Current Problems in Cancer, 2017 Immune checkpoint inhibitors have been approved for a variety of cancer species. Renal complications in use of these agents are not very common compared with other immune-related adverse events (irAE). However, it is crucial for physicians to recognize and manage renal manifestations of irAE.
Naoka, Murakami +2 more
openaire +2 more sources
Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model
Frontiers in Oncology, 2020 Despite the success of immune checkpoint blockade in cancer, the number of patients that benefit from this revolutionary treatment option remains low.
Evelyn Sirait-Fischer +13 more
doaj +1 more source
PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma
Cells, 2021 The dependence of cancer on an immunotolerant tumor microenvironment (TME) is well established. Immunotherapies that overcome tumor-induced immune suppression have been central to recent advancements in oncology.
Joshua W. D. Tobin +3 more
doaj +1 more source
Hallmarks of response to immune checkpoint blockade [PDF]
British Journal of Cancer, 2017 Unprecedented advances have been made in the treatment of cancer through the use of immune checkpoint blockade, with approval of several checkpoint blockade regimens spanning multiple cancer types. However, responses to this form of therapy are not universal, and insights are clearly needed to identify optimal biomarkers of response and to combat ...
Cogdill, Alexandria P +2 more
openaire +2 more sources
Immune Checkpoint Blockade in Cancer Therapy [PDF]
Journal of Clinical Oncology, 2015 Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies. Ipilimumab (CTLA-4) and pembrolizumab (PD-1) are approved by the US Food and Drug Administration for the treatment of ...
Michael A, Postow +2 more
openaire +2 more sources